Redox raises $33m to build health data sharing businessHealth data firm Redox has raised $33 million as it builds its business allowing data sharing between healthcare Share XRedox raises $33m to build health data sharing businesshttps://pharmaphorum.com/news/redox-raises-33m-to-build-health-data-sharing-business/
BI chief “regrets” Brexit, but continues to invest in UKThe head of Germany’s Boehringer Ingelheim has said that he “regrets” Brexit, but reassured patients in the country Share XBI chief “regrets” Brexit, but continues to invest in UKhttps://pharmaphorum.com/news/bi-chief-regrets-brexit-but-continues-to-invest-in-uk/
NICE backs Akcea’s Tegsedi, pipping Alnylam to hATTR okayNICE has recommended that Akcea’s hereditary transthyretin-related amyloidosis (hATTR) treatment Tegsedi be made available on the NHS in Share XNICE backs Akcea’s Tegsedi, pipping Alnylam to hATTR okayhttps://pharmaphorum.com/news/nice-backs-akceas-tegsedi-pipping-alnylam-to-hattr-okay/
Antibody suppresses HIV for four monthsA new antibody has shown potential as treatment for HIV with a mid-stage trial showing it suppressed the Share XAntibody suppresses HIV for four monthshttps://pharmaphorum.com/news/antibody-suppresses-hiv-for-four-months/
Sanofi pledges €10m to Notre Dame, but faces backlashSanofi has said that it will donate 10 million Euros to the rebuilding of Notre Dame cathedral in Share XSanofi pledges €10m to Notre Dame, but faces backlashhttps://pharmaphorum.com/news/sanofi-pledges-e10m-to-notre-dame-but-faces-backlash/
Boehringer’s blockbuster Spiriva under pressure, profits downBoehringer Ingelheim has announced an increase in sales for full year 2018, but a slight decline in profits, Share XBoehringer’s blockbuster Spiriva under pressure, profits downhttps://pharmaphorum.com/news/boehringer-ingelheim-2018-sales-profits/
Catalent acquires gene therapy specialist Paragon for $1.2bnDrug delivery technology provider Catalent is to acquire gene therapy company Paragon for $1.2 billion. Paragon specialises in Share XCatalent acquires gene therapy specialist Paragon for $1.2bnhttps://pharmaphorum.com/news/catalent-acquires-gene-therapy-paragon/
Mesoblast poised to file cell therapy for GVHD in USAustralian biotech Mesoblast can go ahead with a US filing for its off-the-shelf stem cell therapy for acute Share XMesoblast poised to file cell therapy for GVHD in UShttps://pharmaphorum.com/news/mesoblast-cell-therapy-gvhd-fda/
AI firm Insitro signs Gilead as first pharma partner with NASH dealLess than a year after coming out of stealth mode with a $65 million first-round last year, artificial Share XAI firm Insitro signs Gilead as first pharma partner with NASH dealhttps://pharmaphorum.com/digital/ai-insitro-gilead-pharma-partner/
